Timos Papagatsias: Interested in Social Media in the Hematology Space?
Timos Papagatsias, CEO of LucidQuest, shared on LinkedIn:
”Interested in social media in the Hematology space?
Download our ASH24 social media report!
Our team monitored and analyzed ASH-related posts on X (previously Twitter) before, during, and after the event. Here are some key takeaways:
Key Hashtags: mmsm led the discussion, emphasizing Multiple Myeloma, followed by lymsm and leusm. Hashtags like Med Twitter, mpnsm, Moffitt ASH24, MedEd, and Blood Journals also garnered significant traction, reflecting a broad and dynamic conversation around hematological research and treatment.
Top Discussion Themes: Data was the primary focus (~17.7%), highlighting the importance of evidence-based insights.
Efficacy followed closely (~16.2%), with Clinical Trials at ~13.7%. Additional themes around Treatments, patient perspectives, and Safety highlighted the drive towards more effective and patient-centered care.
Leading Voices: Doctors dominated the conversation (~56%), with Education-related and Media accounts contributing ~8% and ~10% respectively.
Research (~12%), Company (~2%), and Advocate (~10%) accounts were also active, while Nurses again scored low (~2%) in high-volume posts.
Audience Sentiment: The sentiment was overwhelmingly positive (~85%), celebrating the event’s educational value and novel insights.
About 10% were neutral, offering real-time updates and general information, while ~5% expressed negative feedback, primarily regarding session overcrowding and issues with the conference app.
Text Analytics: Discussions centered on patient-centric, data-driven approaches in Multiple Myeloma and Lymphoma management.
Treatments like CART therapy and Daratumumab attracted considerable attention, reflecting the growing impact of advanced therapeutics in hematology.
If you’re interested in social media coverage during conferences, send us a message at [email protected]; we cover multiple therapyareas and events!”
Stay updated with Hemostasis Today.
-
Jun 11, 2026, 05:03Aymeric Couturier: Lessons from the TRACK Trial on Anticoagulation in Advanced CKD
-
Jun 11, 2026, 04:53Umut Kocabas: Current Practice and Guideline Adherence on Cancer-Associated Thrombosis in Turkey
-
Jun 11, 2026, 04:40Fernanda Orsi: Which Obstetric APS Patients Are More Likely to Develop Thromboses?
-
Jun 10, 2026, 18:22Winai Porntipworawech: The $50 Life-Saving Drug Big Pharma Doesn’t Want You to See
-
Jun 10, 2026, 18:09Leonard Valentino: Innovation in Blood Disorders Being Catalyzed by Pathway to Cures
-
Jun 10, 2026, 18:00Smitirupa Mishra: Normal Hemoglobin Does Not Always Mean Normal Genes
-
Jun 10, 2026, 17:58Talat Uppal: Addressing HMB with RACGP’s Dr. Ramya Raman
-
Jun 10, 2026, 17:52Throw Back Thursday to Past Bruises Posted in the Glanzmann’s Research Foundation
-
Jun 10, 2026, 17:52Priya Prasad: In Massive Hemorrhage, Fibrinogen Is Often the First Clotting Factor to Fall